Trump presidency signals potential downturn in NIH SBIR/STTR grant funding for biopharma drugs
These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.
‘Very concerning’: What NIH cuts would mean for D.C.-area biotech companies, universities
The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
15 Grants For Minority And Women-Owned Businesses Plus Advice From Grant Winners
A list of 15 grants for minority and women-owned businesses offering $50,000 - $2 million in funding, along with specific ...
GEN4d
As NIH Cuts Loom, Research Organizations Need to Weigh Alternatives
Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
TMCnet7d
Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty
As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial ...
Purdue University6d
National Institutes of Health SBIR/STTR
Both the SBIR and STTR programs are divided into three phases listed below. NIH has special Technical Assistance Programs to help small businesses move their technologies from the lab into the hands ...
Business Wire7d
Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty
As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI), Massive Bio has ...
Science at risk: The funding pause is more damaging than you might think
Several people also said that even minor disruptions can be problematic because researchers typically run extremely lean operations and don't have spare money to cover any shortfalls. "We are already ...
MRKR stock touches 52-week low at $1.8 amid market challenges
In a challenging market environment, Marker Therapeutics Inc. (NASDAQ:MRKR) stock has reached a 52-week low, dipping to $1.8, marking a 70% decline from its 52-week high of $5.99. According to ...